Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors

Pharmacology & Therapeutics
Vincent J AloyoJohn A Harvey

Abstract

Contemporary receptor theory was developed to account for the existence of constitutive activity, as defined by the presence of receptor signaling in the absence of any ligand. Thus, ligands acting at a constitutively active receptor, can act as agonists, antagonists, and inverse agonists. In vitro studies have also revealed the complexity of ligand/receptor interactions including agonist-directed stimulus trafficking, a finding that has led to multi-active state models of receptor function. Studies with a variety of cell types have established that the serotonin 5-HT(2A) and 5-HT(2C) receptors also demonstrate constitutive activity and inverse agonism. However, until recently, there has been no evidence to suggest that these receptors also demonstrate constitutive activity and hence reveal inverse agonist properties of ligands in vivo. This paper describes our current knowledge of constitutive activity in vitro and then examines the evidence for constitutive activity in vivo. Both the serotonin 5-HT(2A) and 5-HT(2C) receptors are involved in a number of physiological and behavioral functions and are the targets for treatment of schizophrenia, anxiety, weight control, Parkinsonism, and other disorders. The existence of constitu...Continue Reading

References

Dec 1, 1991·Biological Psychiatry·R S Kahn, S Wetzler
Jan 1, 1991·Journal of Neural Transmission. General Section·R C Arora, H Y Meltzer
Jan 1, 1990·Life Sciences·D BenjaminL R Meyerson
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·T Costa, A Herz
Dec 1, 1986·Journal of Neurochemistry·P J Conn, E Sanders-Bush
Dec 1, 1985·The Journal of Clinical Endocrinology and Metabolism·E A MuellerT Sunderland
Mar 1, 1995·Trends in Pharmacological Sciences·P Leff
Nov 1, 1994·Trends in Pharmacological Sciences·T Kenakin
Jul 1, 1993·Trends in Pharmacological Sciences·Daniel Hoyer, H W Boddeke
Oct 1, 1993·Archives of General Psychiatry·M LaruelleJ E Kleinman
Oct 1, 1995·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M KuoppamäkiE Syvälahti
Jan 1, 1996·Annual Review of Neuroscience·L Simpson, R B Emeson
Nov 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P W BurnetP J Harrison
Jan 1, 1997·Annual Review of Neuroscience·T GudermannG Schultz
Apr 1, 1997·Current Opinion in Cell Biology·H R Bourne
Apr 1, 1997·Neuropharmacology·Guy KennettT P Blackburn
Aug 1, 1997·Archives of General Psychiatry·S M SouthwickD S Charney
Jan 22, 1998·Proceedings of the National Academy of Sciences of the United States of America·R L Jakab, P S Goldman-Rakic
Feb 26, 1998·Pharmacology, Biochemistry, and Behavior·S E WelshJohn A Harvey
Jun 18, 1998·Psychopharmacology·S E WelshJohn A Harvey
Jan 15, 1999·Pharmacology & Therapeutics·J Wess
Mar 27, 1999·The Journal of Biological Chemistry·C M NiswenderE Sanders-Bush
Aug 5, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·L W FitzgeraldP R Hartig
Mar 17, 2000·Brain Research. Brain Research Reviews·G K Aghajanian, G J Marek
Mar 22, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·T Kenakin
Jul 13, 2001·Journal of Psychopharmacology·H J CassadaylCharles A Marsden
Sep 27, 2001·The Journal of Biological Chemistry·R D PriceE Sanders-Bush
Dec 26, 2001·Brain Research Bulletin·Kelly A Berg, William P Clarke
Mar 13, 2002·Pharmacology, Biochemistry, and Behavior·James R MartinGuy A Higgins
May 31, 2002·Pharmacological Reviews·Arthur Christopoulos, Terry Kenakin
Jun 8, 2002·Current Topics in Medicinal Chemistry·Milt TeitlerAnil Purohit
Oct 17, 2002·Naunyn-Schmiedeberg's Archives of Pharmacology·Roland Seifert, Katharina Wenzel-Seifert
Jan 29, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Helen J CassadayCharles A Marsden
Dec 20, 2003·Current Drug Targets. CNS and Neurological Disorders·Martyn D Wood
Feb 6, 2004·Pharmacology & Therapeutics·David E Nichols
Feb 18, 2004·Current Drug Targets. CNS and Neurological Disorders·J E Leysen
Apr 2, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Philippe De DeurwaerdèreUmberto Spampinato
Jun 26, 2004·Annual Review of Neuroscience·Raul R GainetdinovMarc G Caron
Oct 5, 2006·Current Topics in Medicinal Chemistry·Giuseppe Di GiovanniEnnio Esposito
Oct 20, 2006·Pharmacology & Therapeutics·K D Alex, E A Pehek
Jul 17, 2007·Trends in Pharmacological Sciences·Brian K Kobilka, Xavier Deupi

Citations

Feb 23, 2011·Psychopharmacology·John P Dougherty, Vincent J Aloyo
Jun 12, 2013·Experimental Brain Research·Céline DevroyeUmberto Spampinato
Jun 26, 2010·Nature Reviews. Drug Discovery·C De BodinatMark J Millan
Aug 3, 2012·Journal of Neurophysiology·James R AustgenDavid D Kline
Oct 29, 2010·Journal of Neurophysiology·Katherine C MurrayDavid J Bennett
Feb 13, 2014·Translational Psychiatry·F J MeyeR A H Adan
Dec 19, 2012·Proceedings of the National Academy of Sciences of the United States of America·Rémi BosL Vinay
Mar 25, 2014·Neuroscience and Biobehavioral Reviews·Helio Zangrossi, Frederico G Graeff
Oct 24, 2012·Journal of Psychiatric Research·Antonio Molina-CarballoAntonio Muñoz-Hoyos
Mar 16, 2011·Neuroscience and Biobehavioral Reviews·Dave J Hayes, Andrew J Greenshaw
Jul 29, 2010·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Louise M PatersonGitte M Knudsen
May 4, 2010·Cardiovascular Therapeutics·Stephanie W Watts, Robert Patrick Davis
Apr 20, 2011·The European Journal of Neuroscience·E PearlsteinL Vinay
Sep 17, 2013·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·M P HerringM S Bray
Aug 12, 2014·Human Psychopharmacology·Brian H Harvey, Francois N Slabbert
Apr 15, 2014·British Journal of Pharmacology·B Guardiola-LemaitreElisabeth Mocaer
Jun 19, 2010·CNS Neuroscience & Therapeutics·Giuseppe Di GiovanniVincenzo Di Matteo
Jul 8, 2011·The International Journal of Neuropsychopharmacology·Maria Adrielle Vicente, Helio Zangrossi
Oct 16, 2010·The International Journal of Neuropsychopharmacology·Mark J MillanClotilde Mannoury la Cour
Aug 2, 2011·Vascular Pharmacology·Aslihan Ugun-KlusekShiva Sivasubramaniam
Jul 8, 2008·Neuropharmacology·Kelly A BergUmberto Spampinato
Sep 23, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Svetlana A IvanovaAnton J M Loonen
Mar 16, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Vladimir M PogorelovWilliam C Wetsel
Dec 8, 2016·Behavioural Pharmacology·Alfredo Meneses
Jul 20, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Caleb J BrowneColin Harvey-Lewis
Jun 19, 2018·Journal of Clinical Psychopharmacology·Svetlana A IvanovaAnton J M Loonen
Sep 27, 2018·Journal of Psychopharmacology·Anton J M Loonen, Svetlana A Ivanova
Jul 3, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Amélie SoumierAnnie Daszuta
Sep 27, 2012·Molecular and Cellular Biochemistry·Wagner Santos Coelho, Mauro Sola-Penna
Dec 20, 2011·The Journal of Pharmacology and Experimental Therapeutics·Mark J MillanGilbert Lavielle
Dec 17, 2014·Pharmacological Reviews·Leonard L Howell, Kathryn A Cunningham
Sep 26, 2009·Molecular Pharmacology·Zuzana SaidakRomuald Mentaverri
Mar 28, 2017·Reviews in the Neurosciences·Alfredo Meneses
Nov 22, 2013·Reviews in the Neurosciences·Alfredo Meneses
May 12, 2020·Frontiers in Molecular Neuroscience·Ivan V PozhidaevSvetlana A Ivanova
Jun 30, 2018·The Mental Health Clinician·Jack J Chen
Oct 17, 2017·Frontiers in Neuroanatomy·Noemí Santana, Francesc Artigas
May 19, 2020·Depression and Anxiety·A Irem SonmezPaul E Croarkin
Mar 8, 2020·Neuropharmacology·Noelle C AnastasioKathryn A Cunningham
Apr 4, 2021·Journal of Personalized Medicine·Diana Z PaderinaSvetlana A Ivanova

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Addiction

This feed focuses mechanisms underlying addiction and addictive behaviour including heroin and opium dependence, alcohol intoxication, gambling, and tobacco addiction.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Brain Circuitry in Anxiety

Anxiety impacts the quality of everyday life and may facilitate the development of affective disorders, possibly through concurrent alterations in neural circuitry. Here is the latest research.